Cameron Turtle, Chief Executive Officer at Spyre Therapeutics, Inc. (SYRE), sold 30,000 shares at $29.83 ($871K) on 2025-12-01, disclosed to the SEC on 2025-12-03.
Scheduled sale ($871k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $28.73 | 10,995 | $316K | 36.3% |
| 2 | $28.73 | 10,995 | $316K | 36.3% |
| 3 | $29.83 | 4,005 | $119K | 13.7% |
| 4 | $29.83 | 4,005 | $119K | 13.7% |
| Total | $29.02 avg | 30,000 | $871K | 100% |
| Filing → |
| SYRE | SELL | 2026-08-05 | $1.4M | — | Filing → |
| SYRE | SELL | 2026-07-02 | $1.3M | — | Filing → |
| SYRE | SELL | 2026-06-03 | $1.1M | — | Filing → |